Emerging roles for the FBXW7 ubiquitin ligase in leukemia and beyond

Current Opinion in Cell Biology

Volumn 37, Issue , 2015, Pages 28-34

  Kourtis, Nikos ^a,b   Strikoudis, Alexandros ^a,b   Aifantis, Iannis ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FBXW7 UBIQUITIN LIGASE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; UBIQUITIN;

APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL TRANSDIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIETIC STEM CELL; HUMAN; INTESTINAL STEM CELL; LEUKEMIA; MULTIPLE MYELOMA; NEURAL STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; ANIMAL; ENZYMOLOGY; METABOLISM; STEM CELL;

ANIMALS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; F-BOX PROTEINS; HUMANS; LEUKEMIA; STEM CELLS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84942617442     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2015.09.003     Document Type: Review

References (47)

1. Davis R.J., Welcker M., Clurman B.E. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 2014, 26:455-464.
2. Skaar J.R., Pagan J.K., Pagano M. SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov 2014, 13:889-903.
3. Reavie L., Della Gatta G., Crusio K., Aranda-Orgilles B., Buckley S.M., Thompson B., Lee E., Gao J., Bredemeyer A.L., Helmink B.A., et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol 2010, 11:207-215.
4. Buckley S.M., Aranda-Orgilles B., Strikoudis A., Apostolou E., Loizou E., Moran-Crusio K., Farnsworth C.L., Koller A.A., Dasgupta R., Silva J.C., et al. Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell 2012, 11:783-798.
5. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
6. Stadtfeld M., Maherali N., Borkent M., Hochedlinger K. A reprogrammable mouse strain from gene-targeted embryonic stem cells. Nat Methods 2010, 7:53-55.
7. Okita Y., Matsumoto A., Yumimoto K., Isoshita R., Nakayama K.I. Increased efficiency in the generation of induced pluripotent stem cells by Fbxw7 ablation. Genes Cells 2012, 17:768-777.
8. Matsuoka S., Oike Y., Onoyama I., Iwama A., Arai F., Takubo K., Mashimo Y., Oguro H., Nitta E., Ito K., et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008, 22:986-991.
9. Thompson B.J., Jankovic V., Gao J., Buonamici S., Vest A., Lee J.M., Zavadil J., Nimer S.D., Aifantis I. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med 2008, 205:1395-1408.
10. Iriuchishima H., Takubo K., Matsuoka S., Onoyama I., Nakayama K.I., Nojima Y., Suda T. Ex vivo maintenance of hematopoietic stem cells by quiescence induction through Fbxw7α overexpression. Blood 2011, 117:2373-2377.
11. Siu K.T., Xu Y., Swartz K.L., Bhattacharyya M., Gurbuxani S., Hua Y., Minella A.C. Chromosome instability underlies hematopoietic stem cell dysfunction and lymphoid neoplasia associated with impaired Fbw7-mediated cyclin E regulation. Mol Cell Biol 2014, 34:3244-3258.
12. Clevers H. The intestinal crypt, a prototype stem cell compartment. Cell 2013, 154:274-284.
13. van Es J.H., de Geest N., van de Born M., Clevers H., Hassan B.A. Intestinal stem cells lacking the Math1 tumour suppressor are refractory to Notch inhibitors. Nat Commun 2010, 1:18.
14. Sancho R., Blake S.M., Tendeng C., Clurman B.E., Lewis J., Behrens A. Fbw7 repression by hes5 creates a feedback loop that modulates Notch-mediated intestinal and neural stem cell fate decisions. PLoS Biol 2013, 11:e1001586.
15. Sancho R., Jandke A., Davis H., Diefenbacher M.E., Tomlinson I., Behrens A. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 2010, 139:929-941.
16. Babaei-Jadidi R., Li N., Saadeddin A., Spencer-Dene B., Jandke A., Muhammad B., Ibrahim E.E., Muraleedharan R., Abuzinadah M., Davis H., et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med 2011, 208:295-312.
17. Wise-Draper T.M., Mintz-Cole R.A., Morris T.A., Simpson D.S., Wikenheiser-Brokamp K.A., Currier M.A., Cripe T.P., Grosveld G.C., Wells S.I. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009, 69:1792-1799.
18. Grim J.E., Knoblaugh S.E., Guthrie K.A., Hagar A., Swanger J., Hespelt J., Delrow J.J., Small T., Grady W.M., Nakayama K.I., et al. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol 2012, 32:2160-2167.
19. Faigle R., Song H. Signaling mechanisms regulating adult neural stem cells and neurogenesis. Biochim Biophys Acta 2013, 1830:2435-2448.
20. Hoeck J.D., Jandke A., Blake S.M., Nye E., Spencer-Dene B., Brandner S., Behrens A. Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat Neurosci 2010, 13:1365-1372.
21. Matsumoto A., Onoyama I., Sunabori T., Kageyama R., Okano H., Nakayama K.I. Fbxw7-dependent degradation of Notch is required for control of "stemness" and neuronal-glial differentiation in neural stem cells. J Biol Chem 2011, 286:13754-13764.
22. Raivich G., Bohatschek M., Da Costa C., Iwata O., Galiano M., Hristova M., Nateri A.S., Makwana M., Riera-Sans L., Wolfer D.P., et al. The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron 2004, 43:57-67.
23. Nateri A.S., Riera-Sans L., Da Costa C., Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 2004, 303:1374-1378.
24. Dor Y., Brown J., Martinez O.I., Melton D.A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004, 429:41-46.
25. Sancho R., Gruber R., Gu G., Behrens A. Loss of Fbw7 reprograms adult pancreatic ductal cells into alpha, delta, and beta cells. Cell Stem Cell 2014, 15:139-153.
26. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., Maljukova A., Cepeda D., Fiegl H., Dafou D., Marth C., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67:9006-9012.
27. Hao B., Oehlmann S., Sowa M.E., Harper J.W., Pavletich N.P. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 2007, 26:131-143.
28. Orlicky S., Tang X., Willems A., Tyers M., Sicheri F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 2003, 112:243-256.
29. Welcker M., Larimore E.A., Swanger J., Bengoechea-Alonso M.T., Grim J.E., Ericsson J., Zheng N., Clurman B.E. Fbw7 dimerization determines the specificity and robustness of substrate degradation. Genes Dev 2013, 27:2531-2536.
30. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
31. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
32. Takeishi S., Matsumoto A., Onoyama I., Naka K., Hirao A., Nakayama K.I. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013, 23:347-361.
33. Reavie L., Buckley S.M., Loizou E., Takeishi S., Aranda-Orgilles B., Ndiaye-Lobry D., Abdel-Wahab O., Ibrahim S., Nakayama K.I., Aifantis I. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 2013, 23:362-375.
34. King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Ntziachristos P., Aranda-Orgilles B., Perez-Garcia A., Shi J., Vakoc C., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153:1552-1566.
35. Roderick J.E., Tesell J., Shultz L.D., Brehm M.A., Greiner D.L., Harris M.H., Silverman L.B., Sallan S.E., Gutierrez A., Look A.T., et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 2014, 123:1040-1050.
36. Malyukova A., Brown S., Papa R., O'Brien R., Giles J., Trahair T.N., Dalla Pozza L., Sutton R., Liu T., Haber M., et al. FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. Leukemia 2013, 27:1053-1062.
37. Mansour M.R., Sanda T., Lawton L.N., Li X., Kreslavsky T., Novina C.D., Brand M., Gutierrez A., Kelliher M.A., Jamieson C.H., et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med 2013, 210:1545-1557.
38. Busino L., Millman S.E., Scotto L., Kyratsous C.A., Basrur V., O'Connor O., Hoffmann A., Elenitoba-Johnson K.S., Pagano M. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012, 14:375-385.
39. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
40. Mendillo M.L., Santagata S., Koeva M., Bell G.W., Hu R., Tamimi R.M., Fraenkel E., Ince T.A., Whitesell L., Lindquist S. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 2012, 150:549-562.
41. Kourtis N., Moubarak R.S., Aranda-Orgilles B., Lui K., Aydin I.T., Trimarchi T., Darvishian F., Salvaggio C., Zhong J., Bhatt K., et al. FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat Cell Biol 2015, 17:322-332.
42. Cheng Y., Chen G., Martinka M., Ho V., Li G. Prognostic significance of Fbw7 in human melanoma and its role in cell migration. J Invest Dermatol 2013, 133:1794-1802.
43. Davis M.A., Larimore E.A., Fissel B.M., Swanger J., Taatjes D.J., Clurman B.E. The SCF-Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with mediator. Genes Dev 2013, 27:151-156.
44. Balamurugan K., Sharan S., Klarmann K.D., Zhang Y., Coppola V., Summers G.H., Roger T., Morrison D.K., Keller J.R., Sterneck E. FBXW7alpha attenuates inflammatory signalling by downregulating C/EBPdelta and its target gene Tlr4. Nat Commun 2013, 4:1662.
45. Inuzuka H., Shaik S., Onoyama I., Gao D., Tseng A., Maser R.S., Zhai B., Wan L., Gutierrez A., Lau A.W., et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471:104-109.
46. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., Helgason E., Ernst J.A., Eby M., Liu J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
47. Schulein-Volk C., Wolf E., Zhu J., Xu W., Taranets L., Hellmann A., Janicke L.A., Diefenbacher M.E., Behrens A., Eilers M., et al. Dual regulation of Fbw7 function and oncogenic transformation by Usp28. Cell Rep 2014, 9:1099-1109.